Research Article
Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris

Ralf Müller,1 Nicolas Hunzelmann,2 Vera Baur,1 Guido Siebenhaar,2 Elke Wenzel,1 Rüdiger Eming,1 Andrea Niedermeier,1,3 Philippe Musette,4 Pascal Joly,4 and Michael Hertl1

1 Department of Dermatology and Allergology, University of Marburg, D-35033 Marburg, Germany
2 Department of Dermatology and Venerology, University of Cologne, D-50937 Cologne, Germany
3 Department of Dermatology and Allergology, Ludwig-Maximilian University, D-80337 Munich, Germany
4 Department of Dermatology, Rouen University Hospital, F-7600 Rouen, France

Correspondence should be addressed to Michael Hertl, hertl@med.uni-marburg.de

Received 22 December 2009; Accepted 11 March 2010

Academic Editor: Peter J. Koch

Copyright © 2010 Ralf Müller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In pemphigus vulgaris (PV), IgG autoantibodies against the ectodomain of desmoglein 3 (Dsg3) have been shown to be directly responsible for the loss of keratinocyte adhesion. The aim of the present study was to study the effect of the B cell depleting anti-CD20 monoclonal antibody, rituximab, on the profile of pathogenic IgG against distinct regions of the Dsg3 ectodomain in 22 PV patients who were followed up clinically and serologically by Dsg3 ELISA over 12-24 months. Prior to rituximab, all the 22 PV patients showed IgG against Dsg3 (Dsc3EC1-5). Specifically, 14/22 showed IgG reactivity against the Dsg3EC1 subdomain, 5/22 patients against Dsg3EC2, 7/22 against Dsg3EC3, 11/22 against Dsg3EC4, and 2/22 against Dsg3EC5. Within 6 months after rituximab, all the patients showed significant clinical improvement and reduced IgG against Dsg3 (5/22) and the various subdomains, that is, Dsg3EC1 (7/22), Dsg3EC2 (3/22), Dsg3EC3 (2/22), sg3EC4 (2/22), and Dsg3EC5 (0/22). During the entire observation period, 6/22 PV patients experienced a clinical relapse which was associated with the reappearance of IgG against previously recognized Dsg3 subdomains, particularly against the Dsg3EC1. Thus, in PV, rituximab only temporarily depletes pathogenic B cell responses against distinct subdomains of Dsg3 which reappear upon clinical relapse.

1. Introduction

Pemphigus vulgaris (PV) is a life-threatening autoimmune blistering disease caused by IgG autoantibodies (auto-Ab) against the extracellular domain (ECD) of desmoglein 3 (Dsg3) and Dsg1, desmosomal adhesion molecules present on epidermal keratinocytes [1]. Auto-Ab production in PV is polyclonal, and in active PV, most auto-Ab are of the IgG4 subclass [2, 3]. It has been postulated that auto-Ab against Dsg3 and Dsg1 primarily target the NH2-terminal portion of the Dsg3 ectodomain, that is, the Dsg3EC1 subdomain [4–8]. The EC1 domains of Dsg3 and Dsg1, respectively, according to morphologic studies in desmosomes, are increasingly recognized as the part of the desmosomal cadherin ectodomain which is involved in Dsg transinteraction [9]. Moreover, it seems that IgG auto-Ab reactivity against the Dsg3EC1 domain correlates with active disease in PV although the titers of the auto-Ab do not show a strict correlation with disease activity [10, 11]. Recently, we found a significant correlation between IgG reactivity against Dsg3EC1 and the extent of clinical involvement in PV [8]. IgG against the Dsg3EC1 was seen preferentially in PV patients with mucocutaneous involvement but not in patients with either mucosal or skin involvement only [8].

IgG auto-Ab from pemphigus sera cause loss of adhesion of human skin in vivo and in vitro [12, 13]. Because auto-Ab in pemphigus are directed against desmosomal adhesion molecules, it was suggested that these autoantibodies might directly interfere with Dsg transinteraction binding sites [14–17]. Previous studies showed that IgG against the NH2-terminus of the Dsg3 ectodomain is pathogenic [18]. Affinity-purified IgG of sera from PV patients injected into neonatal mice which were reactive with the EC1 and EC2 of Dsg3, respectively, induced suprabasilar acantholysis, while...
IgG reactive with the EC3-5 of Dsg3 did not [10]. AK23, a mouse monoclonal Ab against Dsg3 which targets the predicted binding motif of the Dsg3EC1, has been shown to be pathogenic in vivo whereas IgG targeting other regions of the Dsg3 ectodomain was not [5, 19]. AK23 directly interferes with homophilic adhesion of two Dsg3 proteins [20] which supports the hypothesis that auto-Ab from PV patients directly inhibit Dsg3-mediated epidermal cell adhesion [21].

Apart from major advances in our understanding of the immune pathogenesis of pemphigus, therapeutic options in cases of recalcitrant pemphigus are rather limited. The standard immunosuppressive treatment of pemphigus consists of systemic glucocorticoids and adjuvant immunosuppressive drugs which induce partial or complete clinical remission in the majority of the patients. In the remaining refractory cases, the B-cell depleting anti-CD20 monoclonal Ab, rituximab, has been recently introduced as a highly effective rescue medication. Rituximab is a chimeric human/mouse IgG1 monoclonal Ab and is directed against CD20, a pan B cell glycoprotein on B lymphocytes from the preB cell to the preplasma-cell stage. Among several mechanisms involved in B cell killing, rituximab exerts B cell cytolytic activity mainly through Ab-dependent cell-mediated cytotoxicity. A plethora of case series and two prospective clinical trials strongly suggest that rituximab is highly effective in recalcitrant pemphigus [22].

In the present study, the impact of rituximab treatment on the profile of Dsg3-specific auto-Ab was studied in a cohort of 22 well-characterized patients with PV. During a 12 to 24 months’ observation period, IgG reactivity against distinct regions of the Dsg3 ectodomain was correlated with clinical parameters such as involvement of body surface area and mucosal surfaces. Our findings suggest that rituximab treatment only temporarily depletes distinct IgG reactivity against the Dsg3 ectodomain and that the reappearance of such auto-Ab is associated with clinical relapses. In particular, IgG reactivity against the NH2-terminal EC1 subregion of the Dsg3 ectodomain was preferentially detected in PV patients who experienced a clinical relapse.

2. Patients and Methods

2.1. PV Patients. Serum samples were obtained from 22 adult patients with PV who were seen at the Dermatology Departments at the Universities of Cologne, Marburg, and Rouen. Patients gave written consent to participate in this study which was adherent to the Declaration of Helsinki Guidelines and which was approved by the local Ethics Committees. The clinical diagnosis of PV was confirmed by (1) histopathology (suprabasal acantholytic blisters), (2) direct immunofluorescence microscopy (epidermal intercellular IgG and/or C3 deposits in perilesional skin), (3) detection of serum IgG auto-Ab by indirect immunofluorescence microscopy (intercellular IgG binding to epithelial cells of monkey esophagus), and (4) by ELISA with recombinant Dsg3 and Dsg1. All the 22 PV patients (mean age: 51.3 ± 13.7 years; 11 females and 11 males) mainly presented with mucocutaneous involvement and elevated anti-Dsg IgG titers (Table 1) despite ongoing (> 3 months) immunosuppressive treatment with systemic corticosteroids (initially 1 mg/kg/d; tapered logarithmically upon clinical response) and the immunosuppressive agents, azathioprine (100–150 mg/day) or mycophenolate mofetil (1-2 g/day), respectively (Table 1).

The clinical extent and severity of PV was classified according to the number of blisters or erosions as either mucosal or cutaneous involvement (the later was quantitated by the body surface area; BSA). All the PV patients were treated i.v. with rituximab at 375 mg/m2 on days 0, 7, 14, and 21 and were kept on an immunosuppressive treatment regimen consisting of prednisolone and azathioprine or mycophenolate mofetil, respectively.

2.2. ELISA with Dsg3 Recombinants. Recombinants representing the entire Dsg3 ectodomain (Dsg3EC1-5) and distinct subregions of the Dsg3 ectodomain, that is, Dsg3EC1-5 (aa 1-566), Dsg3EC1 (aa 1-161), Dsg3EC2 (aa 87-227), Dsg3EC3 (aa 184-349), Dsg3EC4 (aa 313-451) and Dsg3EC5 (aa 424-566) were produced in an eukaryotic baculovirus expression system and were purified using Nickel-NTA as previously described [8, 23]. By ELISA, the patients’ sera were tested for IgG reactivity against the Dsg3 ectodomain (Dsg3EC1-5) as well as IgG reactivity against subdomains of the extracellular portion of Dsg3 as recently described [8, 23]. In short, the recombinant Dsg3 proteins were immobilized on microtiter plates and were incubated with the PV patients’ sera at a dilution of 1:50. IgG binding was visualized as optical density (OD) at 405 nm. Samples were run at least in duplicate and OD’s were expressed as mean values. The threshold for IgG binding of the Dsg3 recombinants in the ELISA yielded an OD value of 0.376 as determined by a ROC curve generated for Dsg3EC1-5 [23]. OD values above the cutoff point defined positive IgG reactivity, while IgG reactivity below the cutoff point was considered to be negative.

2.3. Scoring of Disease Activity in Pemphigus. Scores for mucosal involvement were set as follows: 0, if the patient had no mucosal involvement, 1 point for each additional location of blisters (i.e., oral, dysphagia, genital, conjunctival involvement) and additionally, 1 point for >3 erosions with a diameter ≥2 mm. Skin involvement was assessed by body surface area and was expressed as percentage of affected area.

3. Results

3.1. Clinical Response to Rituximab of the Studied PV Patients. All the 22 PV patients showed a marked clinical response to rituximab treatment which was expressed as dramatically reduced mucosal (baseline: 4.60 ± 1.96; 1.59 ± 1.80 after 6 months) and BSA (baseline: 11.05 ± 13.14; 0.53 ± 1.01 after 6 months) scores within six months after treatment (Figure 1(a)). Among the studied patients, 18/22 (81.8%) had skin involvement and 18/22 (81.8%) mucosal involvement. Except for patient PV6 whose clinical symptoms were unknown, all the PV patients had mucosal
### Table 1: Clinical and immunological characteristics of the pemphigus vulgaris (PV) patients on adjuvant treatment with rituximab.

| Patients | Treatment(1) | Sex | Age | Clinical phenotype of PV(2) | Severity(3) | IgG autoantibody profile(4) |
|----------|--------------|-----|-----|-----------------------------|-------------|-----------------------------|
|          |              |     |     | Mucosa BSA (%) Anti-Dsg1 Anti-Dsg3 |             |                             |
| PV1      | Pred., MMF, Dapson | m   | 53  | mucocutaneous               | 2           | 3 103 549                   |
| PV2      | Pred., MMF, MTX | m   | 67  | mucocutaneous               | 4           | 1 10 484                    |
| PV3      | Pred., MMF, Azathioprin | f   | 69  | mucosal                     | 7           | 0 neg 810                  |
| PV4      | Pred.         | f   | 69  | no mucosal involvement     | 0           | 4 163 2368                |
| PV5      | Pred. MMF, Azathioprin | f   | 37  | mucocutaneous               | 3           | 5 183 94                   |
| PV6      | n.d.          | m   | 48  | n.d.                        | n.d.        | n.d. 979 906               |
| PV7      | Pred., MMF    | m   | 50  | mucocutaneous               | 8           | 1 82 201                   |
| PV8      | Pred., MMF, Dapson | f   | 23  | mucocutaneous               | 2           | 12 357 145                 |
| PV10     | Pred., MMF    | f   | 57  | mucosal                     | 6           | 0 3 124                   |
| PV11     | Pred., MMF, MTX | f   | 28  | mucosal                     | 5           | 0 6 229                   |
| PV12     | Pred., MMF    | f   | 54  | mucocutaneous               | 7           | 5 199 175                 |
| PV13     | n.d.          | m   | 62  | mucocutaneous               | 7           | 10 78 220                 |
| PV14     | Pred.         | m   | 79  | mucocutaneous               | 6           | 10 170 200                 |
| PV15     | Pred.         | m   | 36  | mucocutaneous               | 4           | 60 155 201                 |
| PV16     | n.d.          | m   | 64  | mucocutaneous               | 6           | 20 163 58                 |
| PV17     | Pred.         | f   | 51  | mucocutaneous               | 5           | 10 181 209                |
| PV18     | Pred.         | f   | 70  | mucocutaneous               | 4           | 10 neg 143                |
| PV19     | n.d.          | m   | 59  | mucocutaneous               | 4           | 10 98 156                 |
| PV20     | Pred.         | m   | 38  | mucocutaneous               | 4           | 20 36 138                 |
| PV21     | Pred.         | f   | 41  | mucocutaneous               | 5           | 10 18 119                 |
| PV22     | Pred.         | m   | 24  | mucocutaneous               | 4           | 20 138 135                |
| PV23     | Pred.         | f   | 50  | Mucocutaneous               | 5           | 10 176 163                |

(1) Systemic prednisolone (Pred) was administered throughout the observation period and was logarithmically tapered upon clinical reponse to treatment; azathioprine (AZA) or mycophenolate mofetil (MMF), respectively, was also administered throughout the observation period. n.d., not determined.

(2) Before treatment with rituximab.

(3) Determined by the extent of cutaneous involvement as body surface area (BSA) and the extent of mucosal involvement.

(4) Determined by enzyme-linked immunosorbent assay (ELISA) with recombinant desmoglein (Dsg) 1 and 3; optical densities are expressed as PIV (protein index value).

(5) PIV cutoff is 20.

involvement. Clinical improvement to rituximab was also monitored as a marked reduction of systemic treatment with prednisolone from 0.63 ± 0.60 mg/kg body weight (baseline) to 0.20 ± 0.17 mg/kg body weight (6 months after rituximab treatment) (Figure 1(a)). Noteworthy, 6/22 PV patients experienced a relapse 12 to 24 months after rituximab treatment.

3.2. IgG Titers against Distinct Dsg3 Subdomains and Disease Activity of the PV Patients Are Reduced upon Treatment with Rituximab. IgG auto-ab of the 22 PV patients against the Dsg3 ectodomain and its subdomains was analysed by ELISA during the course of the disease (Figure 1(b)). Prior to treatment with rituximab, all PV patients showed IgG reactivity against at least some part of the entire Dsg3 ectodomain (Dsg3EC1-5), 14/22 showed IgG reactivity against the Dsg3EC1 subdomain, 5/22 patients against Dsg3EC2, 7/22 against Dsg3EC3, 11/22 against Dsg3EC4, and 2/22 against Dsg3EC5. Within 6 months after treatment, there was a marked reduction of IgG reactivity against the Dsg3 ectodomain as well as against distinct subdomains (Figure 1(b)). Because of the availability of patients sera at all time points, the persistence or disappearance of IgG against distinct Dsg3 regions upon treatment with rituximab was studied in more detail in 16 PV patients.

Among these patients, the number of patients with IgG reactivity against the recombinant proteins of Dsg3 of less than 80% of the initial level was studied 6 and 12 months after rituximab (Figure 2). Initially, 16 PV patients showed IgG reactivity against Dsg3EC1-5, 11 against Dsg3EC1, 4 against Dsg3EC2, 5 against Dsg3EC3, 6 against Dsg3EC4, and 2 against Dsg3EC5. Of the 16 patients, a total of 11 showed reduced (by more than 80%) IgG reactivity against the Dsg3 ectodomain (Dsg3EC1-5): Six months after treatment with rituximab, IgG reactivity against Dsg3EC1 was more than 80% reduced in 4/11 patients, against Dsg3EC2 in 1/4 PV patients, against Dsg3EC3 in 3/5 patients against Dsg3EC4 in 4/6, and against Dsg3EC5 in 2/5 patients. Twelve months after treatment with rituximab, IgG reactivity of less than 80% of the initial value was noticed in 11/16 (Dsg3EC1-5), 4/11 (Dsg3EC1), 1/4 (Dsg3EC2), 2/5 (Dsg3EC3), 3/6 (Dsg3EC4) and 2/2 (Dsg3EC5) PV patients. Specifically, the impact of rituximab treatment on IgG reactivity against distinct Dsg3 subdomains is given in Table 2 (0 and 6 months).
3.3. Reappearance of IgG against Distinct Regions of the Dsg3 Ectodomain in PV Patients with Clinical Relapses after Rituximab Treatment. Six of the 22 PV patients treated with rituximab showed a clinical relapse 12 months \((n = 3;\) PV3, PV5, PV6) or 18 months \((n = 3;\) PV13, PV19, PV23), respectively, after rituximab treatment (Table 3). Clinical relapses were defined as newly arisen mucosal or cutaneous lesions which persisted for more than 7 days. All the relapsed PV patients showed increased IgG auto-ab against at least some part of the entire Dsg3 ectodomain (Figure 3) but with individual patterns of IgG recognition of Dsg3 subdomains.

In the individual PV patients, clinical relapses were associated with the reappearance of distinct auto-ab profiles (Figure 3). Four of the 6 relapsed PV patients had IgG against the Dsg3EC1 subdomain prior to rituximab treatment, that is, patients PV3, PV6, PV13, and PV19 (Figure 3). In these PV patients, IgG auto-ab against Dsg3EC1 decreased (PV6, PV13) or remained constant (P3, P19) upon rituximab treatment. Noteworthy, in all these patients, IgG against the Dsg3EC1 persisted until or reappeared at the time of clinical relapse. PV patient PV23 did not initially show IgG against Dsg3EC1 but at the time of relapse 18 months after rituximab treatment.

Only PV patient PV5 had a different auto-ab profile and showed IgG against Dsg3EC3 and Dsg3EC4 prior to rituximab. At the time of clinical relapse 12 months later, he showed IgG against Dsg3EC4 which exceeded pretreatment levels (Figure 3). In patient PV5, IgG against Dsg3EC1 was not detected at the time of clinical relapse. Noteworthy, some of these patients showed IgG reactivity against distinct Dsg3 subdomains in addition to IgG against Dsg3EC1 at the time of clinical relapse. Patient PV3 showed IgG against Dsg3EC1, Dsg3EC2, and Dsg3EC4 when
Figure 3: Association of clinical relapses of rituximab (Rtx)-treated pemphigus vulgaris (PV) patients and the reappearance of IgG against distinct regions of the Dsg3 ectodomain. Three of the 6 PV patients (PV3, PV6, PV23) showed an increase of IgG reactive with the Dsg3EC1 subdomain upon clinical relapse after Rtx therapy. Patient PV13 showed increased serum levels of IgG against the Dsg3EC4 subdomain while patients PV5 and PV19 did not show altered IgG levels against any of the studied Dsg3 subdomains upon clinical relapse.
Table 2: Profile of desmoglein 3 (Dsg3)-specific IgG autoantibodies of the pemphigus vulgaris (PV) patients before and 6 months after treatment with rituximab (Rtx).

| Time point | Dsg3EC1 | Dsg3EC2 | Dsg3EC3 | Dsg3EC4 | Dsg3EC5 |
|------------|---------|---------|---------|---------|---------|
| PV1        | +       | +       | +       | +       | +       |
| PV2        | +       | +       | +       | −       | −       |
| PV3        | +       | +       | −       | −       | +       |
| PV4        | +       | −       | −       | +       | +       |
| PV5        | −       | −       | −       | +       | +       |
| PV6        | +       | −       | −       | −       | −       |
| PV7        | +       | +       | +       | −       | −       |
| PV8        | −       | −       | −       | +       | −       |
| PV9        | −       | −       | −       | +       | −       |
| PV10       | +       | +       | −       | −       | −       |
| PV11       | +       | +       | −       | −       | −       |
| PV12       | +       | +       | −       | +       | +       |
| PV13       | +       | −       | −       | −       | +       |
| PV14       | +       | −       | +       | −       | −       |
| PV15       | −       | −       | −       | −       | −       |
| PV16       | +       | +       | −       | +       | −       |
| PV17       | −       | −       | −       | −       | −       |
| PV18       | −       | −       | −       | +       | −       |
| PV19       | +       | +       | −       | −       | −       |
| PV20       | +       | +       | −       | −       | −       |
| PV21       | +       | +       | −       | +       | −       |
| PV22       | −       | −       | −       | +       | −       |
| PV23       | −       | −       | −       | −       | +       |

Table 3: Synopsis of the IgG autoantibody profile of the pemphigus vulgaris (PV) patients prior to rituximab (preRtx) treatment and at the time of clinical relapse (CR).

| Time point | Dsg3EC1 | Dsg3EC2 | Dsg3EC3 | Dsg3EC4 | Dsg3EC5 |
|------------|---------|---------|---------|---------|---------|
| PV3 (CR, months 12) | + | + | − | + | + |
| PV5 (CR, months 12) | − | − | − | − | − |
| PV6 (CR, months 12) | − | − | + | + | − |
| PV13 (CR, months 18) | + | − | − | − | − |
| PV19 (CR, months 18) | + | − | − | − | − |
| PV23 (CR, months 18) | − | − | − | + | + |

he developed new cutaneous lesions and patient PV5 had IgG against Dsg3EC1, Dsg3EC2, Dsg3EC3, and Dsg3EC4 when he relapsed. Finally, PV patient PV23 showed IgG against Dsg3EC1 and Dsg3EC4 upon clinical relapse. None of the 6 PV patients showed IgG against the COOH-terminal Dsg3EC5 subdomain at the time of clinical relapse (Figure 3).

4. Discussion

The present study strongly suggests that rituximab, a monoclonal antibody against CD20 on B cells, does not permanently deplete pathogenic B cell responses against Dsg3 in patients with PV, a potentially lethal autoimmune bullous disorder of skin and mucosa. Here, a total of 22 patients with refractory PV were treated with rituximab which had been recently identified as a potent treatment in refractory PV [24, 25]. Specifically, these patients did not adequately respond to standard immunosuppressive treatment consisting of high dose systemic corticosteroids combined with the immunosuppressive adjuvants, azathioprine, or mycophenolate mofetil, respectively.

In the cohort of studied patients, all of the 22 PV patients initially showed an excellent clinical response to rituximab.
treatment. However, within 12–18 months after rituximab treatment, 6/22 PV patients experienced a clinical relapse which was associated with the persistence or reappearance of IgG auto-ab against distinct extracellular subdomains of Dsg3, the major autoantigen of PV (Figure 3). The majority, that is, 5/6 of the relapsed PV patients, showed the reappearance of IgG against the NH2-terminal subdomain of Dsg3 which has been previously identified as the site where most of the pathogenic PV auto-Ab bind [11, 19, 26, 27]. In addition, several of the relapsed patients showed IgG reactivity against additional subdomains of Dsg3 most of which had initially disappeared upon treatment with rituximab. Of note, IgG reactivity against the COOH-terminal EC5 subdomain of Dsg3 was not observed in relapsed patients. This region which is located close to the keratinocyte cell membrane is presumably not a target for pathogenic auto-ab in PV [11]. Thus, IgG reactivity against distinct regions of the Dsg3 subdomain which was abolished by rituximab treatment reappeared in these patients at the time of clinical relapse strongly suggesting that the repertoire of Dsg3-specific B cells was only temporarily deleted by rituximab treatment. The frequent detection of Dsg3EC1-specific IgG in clinically relapsed PV patients supports the concept that pathogenic PV auto-ab preferentially target the NH2-terminal EC1 domain of Dsg3. The relative pathogenic role of IgG against Dsg3 subdomains other than Dsg3EC1 awaits further analysis.

The majority, that is, 16/22 PV patients, were successfully controlled by treatment with rituximab and prednisolone over 12 and 24 months, respectively. The other 6 patients showed a clinical relapse during the observation period. Our findings with rituximab are in line with previous reports demonstrating an excellent clinical response associated with a strong reduction of Dsg1- and Dsg3-specific IgG levels on adjuvant treatment with rituximab [2, 25].

Of note, clinical improvement of mucosal and skin lesions of the rituximab-treated PV patients was significantly associated with a decrease of IgG auto-ab titers. However, we did not find any significant correlation between IgG against distinct subdomains of Dsg3 and skin or mucosal involvement. However, our findings suggest that IgG against the Dsg3EC1 domain is associated with active PV as shown earlier by our group and others [5, 8, 11, 23]. The Dsg3 recombinants of the present studies may not contain all the conformational epitopes that are relevant in the immune pathogenesis of pemphigus. However, as proven in two recent reports, these findings with these Dsg3 recombinants are valid and show differential reactivity against distinct portions of the Dsg3 ectodomain in different pemphigus patients and different diseases stages [8, 23].

Recently, we found a significant correlation between IgG reactivity against the Dsg3EC1 and the extent of clinical involvement in PV [8]. IgG against the Dsg3EC1 was seen preferentially in PV patients with muco-cutaneous involvement but not in patients with either mucosal or skin involvement only [8]. IgG auto-ab from pemphigus sera are sufficient to cause blistering in human skin in vivo and in vitro [12, 13] by direct interference with Dsg transinteraction binding sites [14–17].

Previous studies showed that IgG against the NH2-terminus of the Dsg3 ectodomain is pathogenic [18]. Affinity-purified IgG from sera of PV patients injected into neonatal mice which were reactive with the EC1 and EC2 of Dsg3 induced suprabasilar acantholysis, while IgG reactive with the EC3-5 of Dsg3 did not [10]. AK23, a mouse monoclonal ab against Dsg3 which targets the predicted binding motif of the Dsg3EC1, has been shown to be pathogenic in vivo whereas IgG that targets other parts of the Dsg3 ectodomain was not [5, 19]. Additionally, AK23, is able to directly interfere with homophilic Dsg3 binding [20] which supports the hypothesis that auto-ab from PV patients directly inhibit Dsg3-mediated epidermal cell adhesion [21].

Sekiguchi et al. suggested that, both pathogenic and nonpathogenic auto-ab exist in PV [5]. This heterogeneity among anti-Dsg3 antibody due to specific epitope recognition was previously demonstrated [19]. In addition to pathogenic IgG auto-ab against Dsg3EC1, IgG against additional Dsg3 subdomains, that is, DsgEC2, DsgEC3, and DsgEC4, may not be pathogenic per se but may act synergistically in inducing the pathology of intraepidermal loss of adhesion [8]. This contention is supported by a recent study showing that nonpathogenic monoclonal IgG ab that recognize regions of the Dsg3 ectodomain other than the NH2-terminus induce desmosomal loss of adhesion when injected together into mice [28].

Further studies are necessary to investigate the dynamics of pathogenic IgG against the Dsg3EC1 and auto-ab against other Dsg3 subdomains in the immune pathogenesis of PV. At present, it remains to be elucidated why rituximab only temporarily depletes pathogenic auto-ab in PV. Previous observations from our laboratory strongly suggest the presence of short-lived, Dsg3-reactive plasma cells since rituximab rapidly reduced Dsg3-specific IgG auto-ab but not IgG against recall antigens such as tetanus toxoid, Epstein Barr virus or influenza virus [29, 30]. Based on the present and previous observations, detection and monitoring of IgG against the Dsg3EC1 may be a more sensitive marker of disease activity in patients with PV than monitoring IgG against the entire Dsg3 ectodomain.

**Abbreviations**

- Autoantibody: auto-ab
- Dsg: desmoglein
- Dsg3EC1-5: baculoprotein representing the entire ectodomain (aa1-566) of desmoglein 3
- Dsg3EC1: baculoprotein containing aa1-161 of desmoglein 3
- Dsg3EC2: baculoprotein containing aa87-227 of desmoglein 3
- Dsg3EC3: baculoprotein containing aa184-349 of desmoglein 3
- Dsg3EC4: baculoprotein containing aa313-451 of desmoglein 3
- Dsg3EC5: baculoprotein containing aa424-566 of desmoglein 3
- PV: pemphigus vulgaris.
Acknowledgments

The authors thank Eva Podstaw and Andrea Gerber for excellent help with the preparation of recombinant desmoglein 3 proteins and Drs. Claudio Feliciani and Christian Veldman for critical reading of the manuscript and helpful discussions. Financial support for the study was provided by Deutsche Forschungsgemeinschaft (He 1602/8-1 and 1602/8-2 to Michael Hertl and Nicolas Hunzelmann), a Grant from the Rhön-Stiftung of the Universitätsklinikum Giessen und Marburg GmbH (no.103/2006-07 to Michael Hertl) and the German Dermatological Society (DDG, to Ralf Müller). Furthermore, this project was supported by Coordination Theme 1 (Health) of the European Community’s FP7, Grant agreement number HEALTH-F2-2008-200515 (to Rüdiger Eming and Michael Hertl). Michael Hertl and Pascal Joly have been advisors to Roche Inc.

References

[1] M. Amagai, P. J. Koch, T. Nishikawa, and J. R. Stanley, “Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients,” Journal of Investigative Dermatology, vol. 106, no. 2, pp. 351–355, 1996.

[2] A. R. Ahmed, Z. Spigelman, L. A. Cavacini, and M. R. Posner, “Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin,” The New England Journal of Medicine, vol. 355, no. 17, pp. 1772–1779, 2006.

[3] A. Nagel, A. Lang, D. Engel, et al., “Clinical activity of vulgaris relates to IgE autoantibodies against desmoglein 3,” Clinical Immunology, vol. 134, no. 3, pp. 320–330, 2010.

[4] Y. Futei, M. Amagai, M. Sekiguchi, K. Nishifui, Y. Fujii, and T. Nishikawa, “Use of domain-swapped molecules for conformational epitope mapping of desmoglein 3 in pemphigus vulgaris,” Journal of Investigative Dermatology, vol. 115, no. 5, pp. 829–834, 2000.

[5] M. Sekiguchi, Y. Futei, Y. Fujii, T. Iwasaki, T. Nishikawa, and M. Amagai, “Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins,” Journal of Immunology, vol. 167, no. 9, pp. 5439–5448, 2001.

[6] M. K. Hacker-Foegen, M. Janson, M. Amagai, J. A. Fairley, and M.-S. Lin, “Pathogenicity and epitope characteristics of anti-desmoglein-1 from pemphigus foliaceus patients expressing only IgG1 autoantibodies,” Journal of Investigative Dermatology, vol. 121, no. 6, pp. 1373–1378, 2003.

[7] K. Ishii, C. Lin, D. L. Siegel, and J. R. Stanley, “Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies,” Journal of Investigative Dermatology, vol. 128, no. 4, pp. 939–948, 2008.

[8] R. Müller, V. Svoboda, E. Wenzel, H.-H. Müller, and M. Hertl, “IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris,” Experimental Dermatology, vol. 17, no. 1, pp. 35–43, 2008.

[9] A. Al-Amoudi, D. C. Diez, M. J. Betts, and A. S. Frangakis, “The molecular architecture of cadherins in native epidermal desmosomes,” Nature, vol. 450, no. 7171, pp. 832–837, 2007.

[10] M. Amagai, S. Karpati, R. Prussick, V. Klaus-Kovtun, and J. R. Stanley, “Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic,” Journal of Clinical Investigation, vol. 90, no. 3, pp. 919–926, 1992.

[11] V. K. Salato, M. K. Hacker-Foegen, Z. Lazarova, J. A. Fairley, and M.-S. Lin, “Role of intramolecular epitope spreading in pemphigus vulgaris,” Clinical Immunology, vol. 116, no. 1, pp. 54–64, 2005.

[12] J. R. Schiltz and B. Michel, “Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum,” Journal of Investigative Dermatology, vol. 67, no. 2, pp. 254–260, 1976.

[13] G. J. Anhalt, R. S. Labib, and J. J. Voorhees, “Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease,” The New England Journal of Medicine, vol. 306, no. 20, pp. 1189–1196, 1982.

[14] L. Koulu, A. Kusumi, and M. S. Steinberg, “Human autoantibodies against a desmosomal core protein in pemphigus foliaceus,” Journal of Experimental Medicine, vol. 160, no. 5, pp. 1509–1518, 1984.

[15] J. C. R. Jones, K. M. Yokoo, and R. D. Goldman, “A cell surface desmosome-associated component: identification of a tissue-specific cell adhesion molecule,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 19, pp. 7282–7286, 1986.

[16] M. Amagai, V. Klaus-Kovtun, and J. R. Stanley, “Autoantibodies against a novel epithelial cadherin in Pemphigus vulgaris, a disease of cell adhesion,” Cell, vol. 67, no. 5, pp. 869–877, 1991.

[17] P. Sharma, X. Mao, and A. S. Payne, “Beyond steric hindrance: the role of adhesion signaling pathways in the pathogenesis of pemphigus,” Journal of Dermatological Science, vol. 48, no. 1, pp. 1–14, 2007.

[18] K. Ishii, M. Amagai, R. P. Hall, et al., “Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins,” Journal of Immunology, vol. 159, no. 4, pp. 2010–2017, 1997.

[19] K. Tsunoda, T. Ota, M. Aoki, et al., “Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3,” Journal of Immunology, vol. 170, no. 4, pp. 2170–2178, 2003.

[20] W. M. Heupel, W. Baumgartner, B. Laymann, D. Drenckhahn, and N. Golenhofen, “Different Ca2+ affinities and functional implications of the two synaptic adhesion molecules cadherin-11 and N-cadherin,” Molecular and Cellular Neuroscience, vol. 37, no. 3, pp. 548–558, 2008.

[21] J. R. Stanley and M. Amagai, “Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome,” The New England Journal of Medicine, vol. 355, no. 17, pp. 1800–1810, 2006.

[22] M. Hertl, D. Zillikens, L. Borradori, et al., “Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases,” Journal of the German Society of Dermatology, vol. 6, no. 5, pp. 366–374, 2008.

[23] R. Müller, V. Svoboda, E. Wenzel, et al., “IgG reactivity against non-conformational NH2-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris,” Experimental Dermatology, vol. 15, no. 8, pp. 606–614, 2006.

[24] M. Hertl, R. Eming, and L. Borradori, “Rituximab (anti-CD20 monoclonal antibody)—ultimate or first choice in pemphigus?” Dermatology, vol. 214, no. 4, pp. 275–277, 2007.

[25] P. Joly, H. Mouquet, J.-C. Roujeau, et al., “A single cycle of rituximab for the treatment of severe pemphigus,” The New England Journal of Medicine, vol. 357, no. 6, pp. 545–552, 2007.
[26] K. Ishii, R. Harada, I. Matsuo, Y. Shirakata, K. Hashimoto, and M. Amagai, “In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris,” *Journal of Investigative Dermatology*, vol. 124, no. 5, pp. 939–946, 2005.

[27] M. Yokouchi, M. A. Saleh, K. Kuroda, et al., “Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence,” *Journal of Investigative Dermatology*, vol. 129, no. 9, pp. 2156–2166, 2009.

[28] H. Kawasaki, K. Tsunoda, T. Hata, K. Ishii, T. Yamada, and M. Amagai, “Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation,” *Journal of Investigative Dermatology*, vol. 126, no. 12, pp. 2621–2630, 2006.

[29] A. Nagel, M. Hertl, and R. Eming, “B-cell-directed therapy for inflammatory skin diseases,” *Journal of Investigative Dermatology*, vol. 129, no. 2, pp. 289–301, 2009.

[30] A. Nagel, E. Podstawa, M. Eickmann, H.-H. Müller, M. Hertl, and R. Eming, “Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris,” *Journal of Investigative Dermatology*, vol. 129, no. 9, pp. 2202–2210, 2009.